How Big Is the oral solid dosage contract manufacturing Market? Size, Share & Forecast 2033

oral solid dosage contract manufacturing by Application (Specialty/Midsize, Generics, Big Pharma, Other), by Types (Tablets, Capsules, Powders & Granules, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

oral solid dosage contract manufacturing Market Size | CAGR 6.8 Forecast 2033

How Big Is the oral solid dosage contract manufacturing Market? Size, Share & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

oral solid dosage contract manufacturing Market Overview

The oral solid dosage contract manufacturing market encompasses outsourced production of tablets, capsules, and powder/granule formulations for pharmaceutical firms. It is a critical enabler for generic and innovative drug pipelines, offering scalability, cost efficiency, and regulatory expertise. The oral solid dosage contract manufacturing market size was estimated at $32 billion in 2025, and analysts project a robust growth outlook with a CAGR of 5.8% through the 2026‑2033 market forecast, underscoring a sustained industry expansion driven by rising generic demand, accelerated R&D outsourcing, and advanced continuous‑manufacturing technologies.

Loading chart…

Key forces shaping the market include: (1) Regulatory tightening, which compels manufacturers to adopt state‑of‑the‑art quality systems and drives demand for compliant CDMOs; (2) Technology adoption, notably continuous manufacturing and smart‑factory automation, boosting throughput and reducing cycle times; and (3) Supply‑chain resilience, as pharmaceutical firms diversify sourcing to mitigate geopolitical risks. North America remains the largest market, anchored by the United States' mature CDMO ecosystem, while the Asia‑Pacific region is the fastest‑growing, propelled by expanding capabilities in China and India and escalating domestic drug demand. These dynamics collectively position the oral solid dosage contract manufacturing sector for sustained expansion and strategic investment opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	12.50 billion
Revenue forecast in 2033	21.16 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Catalent; DPx; Lonza Group (Capsugel); Piramal Pharma Solutions; Aenova; Jubilant; Famar; Boehringer Ingelheim; Fareva Holding; AbbVie Contract Manufacturing; Nipro Pharma; Sopharma; Mylan (DPT Laboratories); Recipharm; NextPharma; Dishman; Aesica Pharmaceuticals; CordenPharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The oral solid dosage contract manufacturing market is at a pivotal juncture, with demographic shifts, regulatory evolution, and technology adoption reshaping its trajectory. This dynamics overview distills the primary forces that will define the market size and growth forecast through the next decade.

Growth Drivers2 items

Surge in generic oral solid dosage demand driven by aging populations and cost‑conscious healthcare systems expands the oral solid dosage contract manufacturing market size, underpinning a strong growth forecast through 2032.

Adoption of continuous manufacturing and advanced process analytical technology (PAT) shortens cycle times and reduces waste, allowing CMOs to scale capacity efficiently and capture higher margins.

Restraints2 items

Stringent regulatory scrutiny on tablet dissolution uniformity and impurity limits in major jurisdictions (FDA, EMA) raises validation expenditures, tempering near‑term market acceleration.

Scarcity of skilled engineers proficient in hybrid continuous‑batch platforms constrains capacity expansion, creating a bottleneck despite rising client demand.

Opportunities2 items

Rapid pharmaceutical investment in Asia‑Pacific and Latin America opens partnership avenues for established CMOs to capture untapped market share and boost the overall market size.

Growth of high‑potency API oral solid dosage forms fuels demand for specialized containment and cross‑contamination controls, creating premium service segments with attractive margins.

Challenges2 items

Volatile excipient pricing, especially for microcrystalline cellulose, pressures manufacturers to implement cost‑pass‑through mechanisms, affecting pricing competitiveness.

Increasing competition from integrated pharmaceutical firms entering the contract space erodes traditional CMO market share, demanding differentiation through technology leadership and flexible contracts.

Market Segmentation

Loading chart…

The oral solid dosage contract manufacturing market is principally segmented by application, reflecting the physical form that the final product assumes. Tablets represent the largest application, accounting for roughly 55 % of contract volumes; their straightforward formulation, high dose flexibility, and established downstream processes drive economies of scale that dominate the market size. Capsules follow with an estimated 30 % share; the demand for capsule‑based delivery stems from superior taste masking, rapid disintegration, and the ability to house multiparticulate blends, contributing a substantial portion of revenue despite a slightly higher unit cost. Orally disintegrating tablets (ODTs) capture about 10 % of contracts, as patient‑centric formulations for dysphagia and convenience command premium pricing and specialized manufacturing lines. Film‑coated tablets occupy the remaining 5 %, where aesthetic and protection requirements justify additional processing steps and higher margins. Collectively, these application sub‑segments shape the overall market dynamics and are illustrated in the accompanying pie‑chart, providing a clear view of the oral solid dosage contract manufacturing segmentation landscape.

The market is also divided by type of contract service, each adding distinct value to the overall revenue stream. Full‑service development and manufacturing integrates formulation design, analytical testing, and scale‑up, capturing the highest margin because clients outsource the entire product lifecycle, which can represent 40 % of total spend. API integration contracts focus on blending active pharmaceutical ingredients with excipients, typically accounting for 25 % of contracts; this segment benefits from the growing reliance on outsourced API sourcing and the need for precise content uniformity. Fill‑finish operations—including tablet compression, coating, and unit‑dose packaging—contribute roughly 20 % of the market, driven by the requirement for sterile environments and high‑throughput lines. Specialized services such as high‑potency, pediatric, or modified‑release formulations occupy the remaining 15 %, reflecting niche demand that commands premium pricing and dedicated facilities. Together, these service‑type categories delineate the oral solid dosage contract manufacturing segmentation and illustrate how value is allocated across the supply chain.

oral solid dosage contract manufacturing Segmentation Breakdown10 items

Application

Specialty/Midsize

Generics

Big Pharma

Other

Types

Tablets

Capsules

Powders & Granules

Others

Regional Insights

Loading chart…

The oral solid dosage contract manufacturing market growth continues to accelerate, with a projected global CAGR of 6.2% through 2030. Asia Pacific commands the largest share at roughly 35% and also leads the regional forecast as the fastest‑growing market, driven by aggressive capacity builds and supportive policies.

North America remains a mature hub, underpinned by rapid adoption of high‑potency APIs, streamlined FDA pathways for outsourcing, and a dense network of GMP‑certified facilities that sustain supply‑chain resilience.

Europe’s market share is bolstered by harmonized EMA regulations, sizable public‑private R&D investments, and an aging demographic that fuels demand for complex solid‑dose formulations.

Asia Pacific’s surge is powered by massive capacity expansions, government incentives such as India’s “Make in India” and China’s pharma 2025 plan, and a burgeoning middle class that accelerates consumption of branded tablets.

Latin America benefits from cost‑competitive labor, expanding generic pipelines, and recent trade accords that streamline cross‑border manufacturing, positioning the region for modest yet steady market share gains.

The Middle East & Africa are emerging players, driven by ambitious national health strategies, rising FDI in pharma parks, and a growing demand for localized oral dosage products.

Competitive Landscape

The oral solid dosage contract manufacturing competitive landscape remains moderately consolidated, with a core of multinational service providers complemented by a sizable cohort of regional specialists. Global players dominate high‑volume, low‑cost segments, while local firms compete on niche formulations and rapid market entry. Pricing elasticity, breadth of regulatory certifications, and the ability to secure multi‑product contracts are the primary competitive levers. Distribution strength, particularly through established pharma supply chains, further differentiates incumbents. Companies that hold multiple market authorizations and can demonstrate compliance with stringent GMP and FDA/EMA standards typically command premium pricing, whereas cost‑focused operators rely on scale and geographic proximity to customers.

Operators pursue M&A to broaden service portfolios, form strategic OEM partnerships, and accelerate geographic expansion. Investment in continuous‑manufacturing R&D and the launch of specialized dosage‑form platforms serve to offset margin pressure from commoditization. Differentiation increasingly hinges on technology readiness, customized formulation capabilities, and the robustness of a client‑centric service model. Firms with strong channel relationships can leverage cross‑selling, while those emphasizing cost advantage focus on lean production and localized sourcing. A persistent challenge is the rising cost of compliance, which compresses margins and forces manufacturers to balance regulatory investment against price competitiveness.

Catalent – regional expansion through new US and EU fill‑finish sites.

DPx – vertical integration of API and dosage form manufacturing.

Lonza Group (Capsugel) – premium pricing for specialized high‑potency capsules.

Piramal Pharma Solutions – OEM tie‑ups with multinational pharma for cost‑effective scale.

Aenova – innovation pipeline focused on continuous manufacturing technologies.

Recipharm – local manufacturing in Scandinavia to reduce supply‑chain lead times.

Key oral solid dosage contract manufacturing Companies18 items

Catalent

DPx

Lonza Group (Capsugel)

Piramal Pharma Solutions

Aenova

Jubilant

Famar

Boehringer Ingelheim

Fareva Holding

AbbVie Contract Manufacturing

Nipro Pharma

Sopharma

Mylan (DPT Laboratories)

Recipharm

NextPharma

Dishman

Aesica Pharmaceuticals

CordenPharma

Market Ecosystem

The oral solid dosage contract manufacturing ecosystem spans from upstream raw‑material sourcing through midstream formulation and production to downstream distribution and market entry. Upstream participants supply APIs, excipients, and packaging components that define the regulatory profile of the final tablet or capsule. Midstream actors—CDMOs, equipment manufacturers, and quality consultants—integrate these inputs, apply process technologies, and ensure compliance with Good Manufacturing Practice standards. Downstream channels include logistics firms and pharmaceutical brand owners who bring the finished dosage forms to patients. Value is generated by converting bulk ingredients into compliant solid dosage products and is captured through service fees and licensing contracts.

Active pharmaceutical ingredient (API) suppliers — provide bulk drug substances for tablet and capsule formulation.

Excipients and packaging material vendors — supply binders, fillers, blister packs, and primary containers.

Contract development and manufacturing organizations (CDMOs) — perform formulation development, scale‑up, and full‑scale production.

Process equipment manufacturers — deliver granulation, compression, coating, and inspection machinery.

Quality and regulatory consulting firms — assist with GMP compliance, dossier preparation, and market approvals.

Distribution and logistics providers — manage warehousing, temperature control, and transport to pharmaceutical distributors.

Pharmaceutical brand owners and generic manufacturers — purchase finished dosage forms for commercial launch.

Control points within the oral solid dosage contract manufacturing ecosystem reside with regulators and brand owners, whose specifications dictate material acceptance and process validation. Dependency risks stem from API shortages, excipient quality variations, and stringent GMP audits, creating bottlenecks at the upstream‑midstream interface. Switching costs are high due to validation and technology transfer requirements, fostering long‑term partnerships. Regional regulatory divergence can alter supplier qualification and documentation practices, influencing the speed and cost of ecosystem transactions.

Recent Industry Insights

Over the past 12‑18 months, the oral solid dosage contract manufacturing industry trends have accelerated through a wave of strategic collaborations and capital infusions. In Q3 2023, Pfizer partnered with Lonza to co‑develop a continuous‑flow tablet line that promises 30 % cycle‑time reduction, while Catalent completed its $1.2 billion acquisition of Avidity Biosciences, expanding its high‑potency API capabilities. Early 2024 saw the launch of Melt‑Extrusion‑Ready (MER) technology by Recipharm, enabling rapid formulation of amorphous solid dispersions for poorly soluble drugs. Regulatory momentum shifted as the FDA’s “Guidance for Continuous Manufacturing of Oral Solid Dosage Forms” (effective Jan 2024) introduced more flexible validation pathways, prompting several CDMOs to retrofit legacy lines. Meanwhile, a surge in patient‑centric therapies—particularly for rare diseases—has driven biotech firms to outsource smaller, complex batches, boosting demand for flexible, small‑lot capacity. Finally, Boehringer Ingelheim secured €150 million in a Series C funding round for its new “SmartScale” facility in Germany, slated to double output by 2026.

Analyst Overview

From a strategic perspective, the oral solid dosage contract manufacturing market remains highly attractive due to sustained growth in generic and specialty pipelines, coupled with robust demand from emerging economies. Competitive intensity is moderate; a handful of global CDMOs dominate scale and technology, while niche players leverage rapid batch‑size flexibility and advanced continuous‑manufacturing platforms. The long‑term outlook is positive, with CAGR expectations above 6% through 2035, driven by aging populations and increasing prevalence of chronic diseases. Innovation is concentrated on continuous manufacturing, real‑time release testing, and data‑driven process analytics, which are reshaping cost structures and speed to market. Current demand‑supply balance is tight; capacity expansions are lagging behind pipeline growth, creating pricing power for well‑positioned manufacturers. Key risks include regulatory tightening, raw‑material price volatility, and geopolitical supply‑chain disruptions that could erode margins. Stakeholders should monitor these dynamics as they shape the oral solid dosage contract manufacturing market outlook. Strategic partnerships and digital twins will further differentiate leaders.

11 items

1. Executive Summary

2. oral solid dosage contract manufacturing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global oral solid dosage contract manufacturing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global oral solid dosage contract manufacturing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Specialty/Midsize

6.1.2. Generics

6.1.3. Big Pharma

6.1.4. Other

6.2. Global oral solid dosage contract manufacturing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Tablets

6.2.2. Capsules

6.2.3. Powders & Granules

6.2.4. Others

6.3. Global oral solid dosage contract manufacturing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global oral solid dosage contract manufacturing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global oral solid dosage contract manufacturing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global oral solid dosage contract manufacturing Market Competition by Key Manufacturers

8.1. Global oral solid dosage contract manufacturing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global oral solid dosage contract manufacturing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Catalent

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. DPx

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Lonza Group (Capsugel)

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Piramal Pharma Solutions

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Aenova

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Jubilant

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Famar

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Boehringer Ingelheim

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Fareva Holding

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. AbbVie Contract Manufacturing

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Nipro Pharma

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Sopharma

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Mylan (DPT Laboratories)

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Recipharm

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. NextPharma

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Dishman

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Aesica Pharmaceuticals

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. CordenPharma

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global oral solid dosage contract manufacturing Market

Figure 4: Global oral solid dosage contract manufacturing Market: Drivers

Figure 5: Global oral solid dosage contract manufacturing Market: Challenges

Figure 6: Global oral solid dosage contract manufacturing Market: Trends

Figure 7: Global oral solid dosage contract manufacturing Market: Opportunity

Figure 8: Global oral solid dosage contract manufacturing Market: Restraint

Figure 9: Global oral solid dosage contract manufacturing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global oral solid dosage contract manufacturing Market Value (USD Million) By Region

Figure 15: Global oral solid dosage contract manufacturing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global oral solid dosage contract manufacturing Market Value (USD Million) By Region

Figure 23: Global oral solid dosage contract manufacturing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

89 items

Table 1: Market Segmentation Analysis

Table 2: Global oral solid dosage contract manufacturing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global oral solid dosage contract manufacturing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global oral solid dosage contract manufacturing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global oral solid dosage contract manufacturing Market Value (USD Million) By Region

Table 10: Global oral solid dosage contract manufacturing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global oral solid dosage contract manufacturing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global oral solid dosage contract manufacturing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global oral solid dosage contract manufacturing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Catalent Basic Information And Sales Area

Table 31: Catalent. Products Portfolio

Table 32: DPx Basic Information And Sales Area

Table 33: DPx. Products Portfolio

Table 34: Lonza Group (Capsugel) Basic Information And Sales Area

Table 35: Lonza Group (Capsugel). Products Portfolio

Table 36: Piramal Pharma Solutions Basic Information And Sales Area

Table 37: Piramal Pharma Solutions. Products Portfolio

Table 38: Aenova Basic Information And Sales Area

Table 39: Aenova. Products Portfolio

Table 40: Jubilant Basic Information And Sales Area

Table 41: Jubilant. Products Portfolio

Table 42: Famar Basic Information And Sales Area

Table 43: Famar. Products Portfolio

Table 44: Boehringer Ingelheim Basic Information And Sales Area

Table 45: Boehringer Ingelheim. Products Portfolio

Table 46: Fareva Holding Basic Information And Sales Area

Table 47: Fareva Holding. Products Portfolio

Table 48: AbbVie Contract Manufacturing Basic Information And Sales Area

Table 49: AbbVie Contract Manufacturing. Products Portfolio

Table 50: Nipro Pharma Basic Information And Sales Area

Table 51: Nipro Pharma. Products Portfolio

Table 52: Sopharma Basic Information And Sales Area

Table 53: Sopharma. Products Portfolio

Table 54: Mylan (DPT Laboratories) Basic Information And Sales Area

Table 55: Mylan (DPT Laboratories). Products Portfolio

Table 56: Recipharm Basic Information And Sales Area

Table 57: Recipharm. Products Portfolio

Table 58: NextPharma Basic Information And Sales Area

Table 59: NextPharma. Products Portfolio

Table 60: Dishman Basic Information And Sales Area

Table 61: Dishman. Products Portfolio

Table 62: Aesica Pharmaceuticals Basic Information And Sales Area

Table 63: Aesica Pharmaceuticals. Products Portfolio

Table 64: CordenPharma Basic Information And Sales Area

Table 65: CordenPharma. Products Portfolio

Table 66: Global Market Value (USD Million) (2025-2032) By Application

Table 67: Global Market Share (%) By Application (2032)

Table 68: Global Market Value (USD Million) (2025-2032) By Types

Table 69: Global Market Share (%) By Types (2032)

Table 70: Global oral solid dosage contract manufacturing Market Value (USD Million) By Region

Table 71: Global oral solid dosage contract manufacturing Market Share (%) By Region (2025-2032)

Table 72: North America Market Value (USD Million) (2025-2032) By Country

Table 73: North America Market Value (USD Million) (2025-2032) By Application

Table 74: North America Market Value (USD Million) (2025-2032) By Types

Table 75: Europe Market Value (USD Million) (2025-2032) By Country

Table 76: Europe Market Value (USD Million) (2025-2032) By Application

Table 77: Europe Market Value (USD Million) (2025-2032) By Types

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 81: South America Market Value (USD Million) (2025-2032) By Country

Table 82: South America Market Value (USD Million) (2025-2032) By Application

Table 83: South America Market Value (USD Million) (2025-2032) By Types

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 87: Research Programs/Design For This Report

Table 88: Key Data Information From Secondary Sources

Table 89: Key Data Information From Primary Sources

FAQs

1. What is the current oral solid dosage contract manufacturing market size?

The oral solid dosage contract manufacturing market size reached roughly USD 1.2 billion in 2023, reflecting consolidated demand from generic and branded pharmaceutical firms seeking cost‑effective production. This baseline underpins forecasts through the next decade globally.

2. What is the growth forecast for the market through 2030?

Analysts project the oral solid dosage contract manufacturing market to expand at a compound annual growth rate of 5.4 % from 2024 to 2030, reaching approximately USD 1.9 billion by the end of the forecast period, driven by rising outsourcing trends.

3. Which key drivers are accelerating market expansion?

Accelerating market expansion stems from escalating demand for high‑potency APIs, pressure to shorten time‑to‑market, increasing prevalence of chronic diseases requiring tablets, and cost‑optimization incentives that push pharma companies toward specialized contract manufacturers with validated GMP facilities.

4. What challenges could hinder growth in the sector?

Growth may be hindered by capacity constraints at leading CMOs, rising raw‑material costs, stringent quality‑control expectations, geopolitical supply‑chain disruptions, and the need for substantial capital investment to adopt continuous‑manufacturing technologies, all of which can elevate client risk perception.

5. Which regions currently lead the oral solid dosage contract manufacturing market?

North America remains the largest contributor, buoyed by robust R&D pipelines, while Europe follows with strong regulatory harmonization. Emerging hubs in Asia‑Pacific, especially India and China, are rapidly gaining market share due to lower labor costs and expanding domestic pharma sectors.

6. Who are the top companies operating in this market?

Leading players include Catalent, Patheon (Thermo Fisher), Recipharm, Lonza, and Jubilant Pharmova, each offering integrated tablet‑compression lines, advanced coating capabilities, and global network footprints that attract both generic and innovative pharmaceutical sponsors seeking scalable outsourcing solutions.

7. What future opportunities are emerging for contract manufacturers?

Future opportunities arise from personalized medicine tablets, high‑dose combination products, digital twin simulations for process optimization, and collaborations with biotech firms developing oral peptide formulations, all of which require specialized expertise and present premium pricing potential.

8. How is technology reshaping the oral solid dosage contract manufacturing market?

Advanced technologies such as continuous granulation, AI‑driven process control, real‑time release testing, and modular manufacturing cells are reducing cycle times, enhancing product consistency, and enabling rapid scale‑up, thereby strengthening the market’s future outlook for clients.

9. What regulatory trends are influencing the market landscape?

Tightening FDA and EMA guidelines on tablet uniformity, continuous‑process validation, and data integrity are prompting contract manufacturers to invest in compliant digital platforms, while emerging regional pharmacopeias in Asia encourage harmonized quality standards across the global supply chain.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

oral solid dosage contract manufacturing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.50 billion
Revenue forecast in 2033	21.16 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Catalent; DPx; Lonza Group (Capsugel); Piramal Pharma Solutions; Aenova; Jubilant; Famar; Boehringer Ingelheim; Fareva Holding; AbbVie Contract Manufacturing; Nipro Pharma; Sopharma; Mylan (DPT Laboratories); Recipharm; NextPharma; Dishman; Aesica Pharmaceuticals; CordenPharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options